Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer

Fig. 2

Loss of function or inhibition of PLK4 enhances RT induced anticancer effects. Combination of the PLK4 knockdown and RT demonstrates increased anticancer effects, compared to single-agent treatments in (A) MDA-MB-468, (B) MDA-MB-231 and (C) SUM159 cells transfected with either scrambled control (scr) or PLK4-targeting siRNA (siPLK4) and treated with RT (p ≤ 0.05 compared to control (*), RT (α) or siPLK4 (β) only). Combination treatment of (D) MDA-MB-468, (E) MDA-MB-231 and (F) SUM159 cells with RT and PLK4 inhibitor Centrinone B results in decreased colony formation compared to control (*), RT (α) or Centrinone B (β) only (n = 3, p ≤ 0.05). CB– Centrinone B, RT– Radiotherapy, SF– Surviving Fraction

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us